Unexpected findings: 'Promising' drug failed to improve survival in glioblastoma

A three-year research project on a deadly form of brain cancer has revealed that a 'promising' drug therapy failed to improve survival among patients with newly diagnosed glioblastoma. "Bevacizuman had been shown in earlier studies to be an effective drug in the treatment of patients with recurrent disease. But, on newly diagnosed patients, it did not, in fact, prolong survival," state the authors.